Paris, France, January 31, 2014 - Nanobiotix (Euronext: NANO / ISIN: FR0011341205), a clinical- stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today its 2013 annual revenues.

Revenues for the 4th quarter of 2013

As in previous quarters, Nanobiotix revenue for Q4 2013 corresponds to an upfront payment received by the company within the framework of the licensing contract signed with PharmaEngine, in August 2012, which covers the development and commercialization of NBTXR3 in the Asia-Pacific region. The total upfront payment is €810,640, of which €46,351 is the pro rata amount for the period, and €185,030 is for the full year in 2013. The invoicing of services totalled €2,316 for the period. In total, revenues for Q4 2013 were €48,667, giving a total of €190,068 for 2013 which is fully in line with Company expectations.

As a reminder, PharmaEngine has committed to pay a maximum additional amount of US$56 million depending on the completion of different milestones and development of the clinical program. Furthermore, Nanobiotix could receive double-digit royalties on net product sales in the Asian-Pacific region.

Public funding for research expenditures, which comprises a research tax credit, is not included in the revenues but is part of the Company's operating revenues, released with the half and full year results.

2013 - A successful year in terms of clinical progress

As a reminder, the NanoXray pipeline progressed significantly over the past 12 months. Lead product NBTXR3 achieved clinical proof-of-concept, and the two other products of the pipeline, NBTX-IV and NBTX-TOPO, reached major preclinical milestones.

Click on the following link to download the 2013 review of the NanoXray pipeline progress

2013: significant progress for Nanobiotix

Nanobiotix and the ETPN partners at the Second Nano World Cancer Day

Within the framework of the World Cancer Day, Nanobiotix led the French element at the Nano World Cancer Day, European press conference, coordinated by the European Technology Platform on Nanomedicine (ETPN). The event occurred simultaneously in 13 countries within Europe and was an opportunity to highlight the present and future nanomedicine benefits and its range of applications against cancer, from diagnostic to therapeutic perspectives. As Vice-Chairman of the ETPN, Laurent Levy, CEO of Nanobiotix, took part in this conference, alongside recognized industrials among healthcare sector.

For more information, click here

Promising outlook for 2014

For Nanobiotix, 2014 will be a pivotal year for the company, during which we expect to achieve several significant milestones.

In terms of clinical development, Nanobiotix is expecting final results from the phase I study initiated in France on soft tissue sarcoma, the first intermediate results from the clinical study on head and neck cancers and anticipating the regulatory authorization for the start of the clinical trial in liver cancer within the framework of the NICE project. At the international level, Nanobiotix will be focused on its ambitious partnership policy with the initiation of two trials led by PharmaEngine in Asia and will be targeting the US territory [for development partners].

To support these key developments, the Nanobiotix management nominated Anne-Marie GRAFFIN (as a member) and Enno SPILLNER (as observer) to the Supervisory Board in January 2014. This is in addition to the recruitment of Philippe MAUBERNA as Chief Financial Officer and Sarah GAUBERT as Head of Communication and Public Affairs, in H2 2013 to strengthen the management team and the corporate governance.

We believe we are making major strides in our development and have the right team in place to fulfil our strategy and ambitions to make a significant impact in the field of nanomedicine.

distributed by